Semaglutide weight-loss medications increase the risk of androgenetic alopecia by seven percent in men with a genetic predisposition to hair loss, according to a study published by researchers at NYU Langone Health in the Journal of Investigative Dermatology. The findings establish the first genetic link between GLP-1 medications and hereditary hair thinning, suggesting that physicians may eventually need to screen specific patients for hair loss risk before starting treatment.
Genetic Links Between GLP-1 Medications and Hair Loss
Researchers at NYU Langone Health evaluated genetic databases covering more than 200,000 predominantly white men to determine whether weight-loss drugs trigger distinct dermatological side effects. According to the study published in the Journal of Investigative Dermatology, the investigation focused specifically on the GLP1R gene, which regulates naturally occurring GLP-1 levels in the human body. By cross-referencing these genetic markers with known genes responsible for male pattern baldness, study lead Lynn Petukhova stated that the work provides the first genetic link between GLP-1 use and an elevated risk of androgenetic alopecia, noting an overall seven percent increased risk.
Distinguishing Medication Side Effects From Rapid Weight Loss
Clinical observations of patients taking medications containing semaglutide frequently include reports of hair shedding. Active pharmaceutical ingredients like semaglutide mimic the natural gut hormone GLP-1, slowing gastric emptying, regulating blood sugar, enhancing satiety in the brain, and suppressing appetite. Prior to the NYU Langone Health study, researchers attributed hair loss to the rapid weight loss caused by the medications. Patients experiencing weight-loss-related shedding typically notice hair regrowth a few months after their weight stabilizes. However, the new genetic findings indicate that GLP-1 receptor activation interacts with the biological pathways governing hereditary hair loss at the crown and hairline.
Future Screening and Preventive Care Considerations
With approximately 12 percent of Americans having used GLP-1 medications for weight loss, identifying specific vulnerability factors remains a clinical priority. In the United States, roughly half of all white men over the age of 50 experience androgenetic alopecia, establishing a large baseline population affected by the hereditary condition. According to Lynn Petukhova, further research is necessary to understand the exact biological mechanisms and investigate whether female patients face similar risks. If subsequent studies are successful, physicians might implement pre-treatment screenings for hair loss vulnerability and potentially prescribe preventive treatments alongside initial GLP-1 therapy.
Worth a look